Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for ...

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and ...

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.

The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces ...

In its budget request, the agency proposed a way to speed up early drug testing and help smaller biotech firms. Elsewhere, two startups raised megarounds.

The Participant Perks Card offers a wide range of benefits for study organizers and participants alike, including: Simplifies ...

A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed ...

A collaboration “across multiple therapeutic areas” could net the Hong Kong-based biotech more than $2 billion as Lilly seeks ...